2022 DOI: 10.1016/S0140-6736(22)02033-5 PMID: 36354040 Read on PubMed The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock J, Frias J, Jastreboff AM, et al
Brum, J
With the increasing prevalence of metabolic diseases globally, interventions targeting GLP-1R could play an important role in reducing the burden of these conditions
Weight loss patches are topical products applied to the skin that claim to deliver ingredients transdermally
Thus, these results showed a strong glucose-lowering effects towards a nearly-normal range with weight loss of a not previously reported extent in people with T2DM and without increased risk of clinically significant hypoglycemia [24]
Of course, we have seen weight-loss hype before